Wednesday, June 10, 2026
🇺🇸 FDA

P1 · Therapeutic area intelligence

Oncology patent intelligence

Anticancer agents, immuno-oncology, ADC, and oncology patent filings — grants, expirations, and assignee activity.

Patents
2,004

Quick answer

2,004 US pharmaceutical patents in our index match Oncology title keywords (A61K/A61P). Cross-link to related drug therapeutic-area hubs and company patent portfolios for full IP context.

  1. US 11779660

    Viral vectors for cancer therapy

    Krystal Biotech, Inc. · Granted Tue Oct 10 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11771748

    Methods for treating tumor-induced osteomalacia

    Ultragenyx Pharmaceutical Inc. · Granted Tue Oct 03 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11767367

    Monoclonal antibody neo-201 for the treatment of human carcinomas

    PRECISION BIOLOGICS, INC. · Granted Tue Sep 26 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11760795

    Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia and cancer

    Julius-Maximilians-Universitat Wurzburg · Granted Tue Sep 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11759461

    Small molecule inhibitors of cancer stem cells and mesenchymal cancer types

    THE UNIVERSTY OF TEXAS SYSTEM,BOARD OF REGENTS · Granted Tue Sep 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11760803

    Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments

    Takeda Pharmaceutical Company Limited · Granted Tue Sep 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. CA 3245150

    COMBINAISONS AVEC UN ANTICORPS ANTI-CD39 HUMAIN, UN ANTICORPS ANTI-PD-1 HUMAIN ET UNE CHIMIOTHÉRAPIE CONTRE LE CANCER GASTRIQUE

    TRISHULA THERAPEUTICS INC [US] · Granted Thu Sep 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Sep 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11746151

    Compositions and methods for treating cancer

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Sep 05 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 31 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11746152

    Methods of cancer treatment and therapy using a combination of antibodies that bind glycosylated PD-L1

    The Board of Regents of the University of Texas System · Granted Tue Sep 05 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 31 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11739297

    Method of increasing tumor killing activity of macrophages or monocytes comprising chimeric antigen receptor

    Carisma Therapeutics Inc. · Granted Tue Aug 29 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 24 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11738009

    Bicyclic compounds and their use in the treatment of cancer

    TEMPEST THERAPEUTICS, INC. · Granted Tue Aug 29 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 24 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11730799

    Cancer vaccines and methods of producing and using same

    THE UNITED STATES GOVERNMENT DEPARTMENT OF VETERANS AFFAIRS · Granted Tue Aug 22 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 17 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11725248

    Evaluation of mantle cell lymphoma and methods related thereto

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Aug 15 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 10 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11723922

    CXCR6-transduced T cells for targeted tumor therapy

    Ludwig-Maximilians-Universitat Munchen · Granted Tue Aug 15 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 10 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11718658

    T cell receptors that bind to mixed lineage leukemia (MLL)-specific phosphopeptides and methods of use thereof

    MiNK Therapeutics, Inc. · Granted Tue Aug 08 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 03 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11717542

    Using tumor-navigating Salmonella to modulate tumor metabolism

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Tue Aug 08 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 03 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11718630

    Compositions and methods for treating cancer

    The Regents of the University of California · Granted Tue Aug 08 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 03 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11717573

    Methods and compositions for the treatment of cancer

    SOUTH DAKOTA BOARD OF REGENTS · Granted Tue Aug 08 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 03 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 11714089

    Combination of markers for diagnosing cancer

    The Medical Research, Infrastructure and Health Services Fund of the Tel-Aviv Medical Center · Granted Tue Aug 01 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 27 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 11713446

    Processes for generating TIL products enriched for tumor antigen-specific T-cells

    Iovance Biotherapeutics, Inc. · Granted Tue Aug 01 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 27 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 11712474

    Reduction of post-surgery cancer metastasis by combination of cannabidiol and NR2F6 inhibition

    Regen Biopharma, Inc. · Granted Tue Aug 01 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 27 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 11708352

    Anti-cancer compounds

    The Regents of the University of California · Granted Tue Jul 25 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 11702657

    TRNA/pre-miRNA compositions and methods for treating hepatocellular carcinoma

    The Regents of the University of California · Granted Tue Jul 18 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 11702701

    Means and methods for staging, typing and treating a cancerous disease

    Universität Regensburg · Granted Tue Jul 18 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 11696922

    Nanoparticle to target cancer

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jul 11 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 06 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 11699503

    Methods of identifying and treating patient populations amenable to cancer immunotherapy

    The Regents of the University of California · Granted Tue Jul 11 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 06 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 11690851

    Methods and compositions comprising ursolic acid and/or resveratrol for treating diabetes, or cancer

    The Board of Regents of the University of Texas System · Granted Tue Jul 04 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 29 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. WO 2023118508

    VIRUS MVA RECOMBINANTS POUR ADMINISTRATION INTRAPÉRITONÉALE POUR LE TRAITEMENT DU CANCER

    BAVARIAN NORDIC AS [DK] · Granted Thu Jun 29 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Jun 24 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 11685775

    Method of increasing the ratio of effector T cells to regulatory T cells in a tumor by administering to a subject a TGF-beta inhibitor and a PD-1 antibody

    The Regents of the University of California · Granted Tue Jun 27 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 22 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 11684626

    Methods and compositions comprising ursolic acid and/or resveratrol for treating obesity, diabetes, or cancer

    The Board of Regents of the University of Texas System · Granted Tue Jun 27 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 22 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 11679128

    Methods of producing enriched populations of tumor reactive T cells from peripheral blood

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jun 20 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 15 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 11679112

    Cancer treatments using combinations of CDK and ERK inhibitors

    Biomed Valley Discoveries, Inc. · Granted Tue Jun 20 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 15 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 11680067

    Small molecules for the treatment of primary cancer and cancer metastasis

    The Board of Regents of the University of Texas System · Granted Tue Jun 20 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 15 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 11680105

    Antibody fragments for detecting cancer and methods of use

    Regents of the University of Minnesota · Granted Tue Jun 20 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 15 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 11679121

    Morpholino oligonucleotides useful in cancer treatment

    United States Government as represented by the Department of Veterans Affairs · Granted Tue Jun 20 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 15 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 11679113

    Anticancer treatment for uveal melanoma

    The Regents of the University of California · Granted Tue Jun 20 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 15 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 11672801

    Compositions and methods for treating cancer

    United States Government as represented by the Department of Veterans Affairs · Granted Tue Jun 13 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 11672794

    Therapeutic targeting of the BAP1 complex in cancer

    Northwestern University · Granted Tue Jun 13 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 11673966

    Monoclonal and humanized antibodies to a cancer glycopeptide

    The Board of Regents of the University of Texas System · Granted Tue Jun 13 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 11672774

    Methods of treating squamous cell carcinomas with farnesyltransferase inhibitors

    Kura Oncology, Inc. · Granted Tue Jun 13 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 11667718

    Cancer treatment

    VANDA PHARMACEUTICALS INC. · Granted Tue Jun 06 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 11667900

    Compositions and methods for enhancing macrophage-mediated antibody guided cancer cell or tumor eradication

    The Regents of the University of California · Granted Tue Jun 06 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 11667890

    Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion

    Iovance Biotherapeutics, Inc. · Granted Tue Jun 06 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 11660295

    Glucocorticoid receptor modulators to treat cervical cancer

    Corcept Therapeutics Incorporated · Granted Tue May 30 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 25 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 11660325

    Compositions and methods of targeting cancer stem cells

    The Board of Regents of the University of Texas System · Granted Tue May 30 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 25 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 11654193

    Cancer treatment combinations

    The Regents of the University of California · Granted Tue May 23 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 18 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 11654157

    Methods and compositions for cancer therapies that include delivery of halogenated thymidines and thymidine phosphorylase inhibitors in combination with radiation

    Shuttle Pharmaceuticals, Inc. · Granted Tue May 23 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 18 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. CA 3240096

    POLYTHERAPIE POUR LE TRAITEMENT DU CANCER DU POUMON

    NOVARTIS AG [CH] · Granted Fri May 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Thu May 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many Oncology patents are indexed?

2,004 patents match our Oncology classifier (title keywords in USPTO records).

Is this legal or medical advice?

No — patent intelligence is for professional reference. Verify expiration and FTO with qualified patent counsel and primary USPTO records.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.